Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
For patients with multidrug-resistant HIV who've tried nearly everything, fostemsavir is proving its worth. A French real-world study found that 91% of already-suppressed patients maintained viral control on fostemsavir-based therapy, while 63% of those with detectable virus achieved suppression — far outpacing ibalizumab-based regimens at 36%. It's a meaningful win for one of HIV's toughest-to-treat populations.
For people with HIV who've exhausted most treatment options, finding a regimen that works is a serious challenge. A new real-world study out of France offers encouraging news for this heavily treatment-experienced (HTE) population: fostemsavir-based antiretroviral therapy delivered strong and durable viral suppression across the board.
The retrospective study followed 81 patients — 70 on fostemsavir and 11 on ibalizumab — all of whom had extensive prior treatment histories and often harbored multidrug-resistant HIV-1. At last follow-up, 78% of fostemsavir recipients had viral loads below 50 copies/mL, with a median follow-up of 20 months. Ibalizumab recipients fared considerably worse, with only 36% achieving suppression and 46% experiencing virologic failure.
By the Numbers:
Why it matters: Options are limited for HTE patients with multidrug-resistant HIV, making real-world evidence on newer agents like fostemsavir especially valuable. These findings support fostemsavir as a reliable long-term option for treatment optimization in this difficult-to-manage population.
